Search Results - "Du Four, S."

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma by Duerinck, J., Du Four, S., Bouttens, F., Andre, C., Verschaeve, V., Van Fraeyenhove, F., Chaskis, C., D’Haene, N., Le Mercier, M., Rogiers, A., Michotte, A., Salmon, I., Neyns, B.

“…Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors. It…”
Get full text

Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma by Duerinck, J., Du Four, S., Vandervorst, F., D’Haene, N., Le Mercier, M., Michotte, A., Van Binst, A. M., Everaert, H., Salmon, I., Bouttens, F., Verschaeve, V., Neyns, B.

“…We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule…”
Get full text

Deep brain stimulation in Bassen-Kornzweig syndrome: Still effective after 22 years by Cortier, J., Vandamme, S., Vanhauwaert, D., Maenhoudt, W., Van Lerbeirghe, J., Tack, P., Du Four, S., Van Damme, O.

“…Bassen-Kornzweig syndrome or abetalipoproteinemia is a rare autosomal recessive disorder characterized by a malabsorption of dietary fat and fat-soluble…”
Get full text

Prognostic value of 0-(2-[18F]-fluoroethyl)-L-tyrosine PET in patients with recurrent GBM by Geens, W., Du Four, S., Van Laere, S., Schwarze, J.K., Awada, G., Tijtgat, J., Bruneau, M., Everaert, H., Neyns, B., Duerinck, J.

Get full text

O10.07 RANDOMIZED PHASE II STUDY OF AXITINIB VS. STANDARD OF CARE IN PATIENTS WITH RECURRENT GLIOBLASTOMA by Duerinck, J., Du Four, S., Bouttens, F., Verschaeve, V., Everaert, H., De Raedt, S., Van Binst, A., Neyns, B.

“…INTRODUCTION: Glioblastoma (GB) associated neo-angiogenesis is mediated by vascular endothelial growth factor receptor (VEGFR) signal transduction. Axitinib is…”
Get full text

O1.05 AXITINIB, A SELECTIVE VEGFR-1,-2,-3 TYROSINE KINASE INHIBITOR, INHIBITS TUMOR GROWTH AND INCREASES INFILTRATION OF IMMUNE CELLS IN AN INTRACRANIAL MELANOMA MOUSE MODEL by Du Four, S., Maenhout, S. K., Niclou, S. P., Thielemans, K., Neyns, B., Aerts, J. L.

“…VEGF is a key mediator of pathological cancer associated neoangiogenesis and immunosuppression. VEGFR targeted therapy holds promise to counteract cancer…”
Get full text

P16.09 VALUE OF FET-PET EVALUATION IN PATIENTS TREATED WITH AXITINIB by Duerinck, J., Du Four, S., De Raedt, S., Everaert, H., Van Binst, A., Neyns, B.

“…INTRODUCTION: VEGF/VEGFR targeted therapy for recurrent glioblastoma (rGB) normalizes tumour vasculature and restores the blood-brain barrier (BBB), resulting…”
Get full text

Erections Upon Walking. A Less Known Symptom of Lumbar Canal Stenosis by Duerinck, J, Van Rompaey, K, Van Der Veken, J, Du Four, S, Ampe, B, Moens, M, D'Haens, J

Get full text

Sarcoidosis in a Patient with Metastatic Melanoma Sequentially Treated with Anti-CTLA-4 Monoclonal Antibody and Selective BRAF Inhibitor by WILGENHOF, Sofie, MORLION, Veerle, SEGHERS, Amélie Clémentine, FOUR, Stephanie Du, VANDERLINDEN, Esther, HANON, Shane, VANDENBROUCKE, Frederik, EVERAERT, Hendrik, NEYNS, Bart

“…A female patient with stage IV-M1c (distant lymph node and breast metastases), chemotherapy-refractory melanoma was treated with the cytotoxic T-lymphocyte…”
Get full text

P08.09 Axitinib for the treatment of patients with recurrent glioblastoma, final results from a randomized phase II clinical trial by Duerinck, J., Du Four, S., Bouttens, F., Verschaeve, V., Andre, C., Van Fraeyenhove, F., Chaskis, C., D’haene, N., Salmon, I., Neyns, B.

Get full text

O1.05AXITINIB, A SELECTIVE VEGFR-1,-2,-3 TYROSINE KINASE INHIBITOR, INHIBITS TUMOR GROWTH AND INCREASES INFILTRATION OF IMMUNE CELLS IN AN INTRACRANIAL MELANOMA MOUSE MODEL by Du Four, S., Maenhout, S.K., Niclou, S.P., Thielemans, K., Neyns, B., Aerts, J.L.

“…VEGF is a key mediator of pathological cancer associated neoangiogenesis and immunosuppression. VEGFR targeted therapy holds promise to counteract cancer…”
Get full text

P16.09VALUE OF FET-PET EVALUATION IN PATIENTS TREATED WITH AXITINIB by Duerinck, J., Du Four, S., De Raedt, S., Everaert, H., Van Binst, A., Neyns, B.

“…INTRODUCTION: VEGF/VEGFR targeted therapy for recurrent glioblastoma (rGB) normalizes tumour vasculature and restores the blood-brain barrier (BBB), resulting…”
Get full text

O10.07RANDOMIZED PHASE II STUDY OF AXITINIB VS. STANDARD OF CARE IN PATIENTS WITH RECURRENT GLIOBLASTOMA by Duerinck, J., Du Four, S., Bouttens, F., Verschaeve, V., Everaert, H., De Raedt, S., Van Binst, A., Neyns, B.

“…INTRODUCTION: Glioblastoma (GB) associated neo-angiogenesis is mediated by vascular endothelial growth factor receptor (VEGFR) signal transduction. Axitinib is…”
Get full text

CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma by Verschaeve, V., D'Hondt, L. A., Verbeke, L. M. J., Van Fraeyenhove, F., Du Four, S., Duerinck, J., Neyns, B.

“…Abstract only…”
Get full text

Deep brain stimulation in Bassen-Kornzweig syndrome: Still effective after 22 years by Cortier, J, Vandamme, S, Vanhauwaert, D, Maenhoudt, W, Van Lerbeirghe, J, Tack, P, Du Four, S, Van Damme, O

“…IntroductionBassen-Kornzweig syndrome or abetalipoproteinemia is a rare autosomal recessive disorder characterized by a malabsorption of dietary fat and…”
Get full text